A multi-arm, adaptive, group sequential research network for individuals affected by amyotrophic lateral sclerosis, aiming to investigate the effectiveness of treatments. The research network is organised by TRICALS. The current study arm aims to compare the effect of the drug Lithium Carbonate (Lithium) with a placebo.

This is a phase III, multi-arm, double-blind, randomised, placebo-controlled study.

Lithium is a drug, currently approved and registered, to treat mood disorders. However, lithium affects multiple biological mechanisms involved in amyotrophic lateral sclerosis. Previous research has shown that the drug has, potentially, an inhibitory effect in patients affected by ALS with a variation in the UNC13A gene.

Based on DNA testing, the investigator will determine your eligibility to participate in this study. Only patients with a variation in the UNC13A gene are eligible to participate. You have a 2/3 chance of receiving the active substance and a 1/3 chance of receiving a placebo.

Are you interested, or would you like more information? Contact us at onderzoek@als.be.

More info on this study can be found on the website, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000579-19/NL